BRPI1009606A2 - método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição - Google Patents
método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composiçãoInfo
- Publication number
- BRPI1009606A2 BRPI1009606A2 BRPI1009606A BRPI1009606A BRPI1009606A2 BR PI1009606 A2 BRPI1009606 A2 BR PI1009606A2 BR PI1009606 A BRPI1009606 A BR PI1009606A BR PI1009606 A BRPI1009606 A BR PI1009606A BR PI1009606 A2 BRPI1009606 A2 BR PI1009606A2
- Authority
- BR
- Brazil
- Prior art keywords
- multiple sclerosis
- treating
- microparticle
- symptoms
- linked
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photographic Developing Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
| PCT/NZ2010/000112 WO2010147484A1 (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1009606A2 true BRPI1009606A2 (pt) | 2016-10-11 |
Family
ID=42646236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1009606A BRPI1009606A2 (pt) | 2009-06-16 | 2010-01-16 | método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8389479B2 (https=) |
| EP (1) | EP2442832B1 (https=) |
| JP (1) | JP5646617B2 (https=) |
| CN (1) | CN102458476B (https=) |
| AU (1) | AU2010260585B2 (https=) |
| BR (1) | BRPI1009606A2 (https=) |
| CA (1) | CA2688766C (https=) |
| CY (1) | CY1115714T1 (https=) |
| DK (1) | DK2442832T3 (https=) |
| ES (1) | ES2521565T3 (https=) |
| HR (1) | HRP20141035T1 (https=) |
| IL (1) | IL216993A (https=) |
| IN (1) | IN2012DN00167A (https=) |
| MX (1) | MX2011013661A (https=) |
| NZ (1) | NZ577731A (https=) |
| PL (1) | PL2442832T3 (https=) |
| PT (1) | PT2442832E (https=) |
| SI (1) | SI2442832T1 (https=) |
| SM (1) | SMT201400165B (https=) |
| WO (1) | WO2010147484A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009123480A1 (en) * | 2008-04-01 | 2009-10-08 | Virionyx Corporation Ltd | Anti-infective agents and uses thereof |
| HUE050713T2 (hu) * | 2010-10-25 | 2020-12-28 | Biogen Ma Inc | Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2017059486A1 (en) * | 2015-10-06 | 2017-04-13 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of epilepsy |
| CA2926507A1 (en) * | 2015-10-06 | 2017-04-06 | Innate Immunotherapeutics Limited | Compositions and methods for protection and/or repair of the nervous system |
| WO2017070731A1 (en) * | 2015-10-28 | 2017-05-04 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of alzheimer's disease |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| HUE071047T2 (hu) | 2016-08-31 | 2025-07-28 | Mapi Pharma Ltd | Glatiramer-acetátot tartalmazó depórendszerek |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| CA3099946A1 (en) * | 2018-05-18 | 2019-11-21 | Universite Laval | Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease |
| WO2020010221A1 (en) * | 2018-07-03 | 2020-01-09 | University Of Florida Research Foundation, Inc. | Microparticle systems and their use for the treatment of multiple sclerosis |
| US20230190570A1 (en) * | 2020-06-22 | 2023-06-22 | Otivio As | Methods for treating spasticity using anti-spasmodic compositions and negative pressure therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327896C (zh) * | 1996-10-10 | 2007-07-25 | 探针国际公司 | 治疗病毒感染的组合物及方法 |
| JP2008505130A (ja) * | 2004-07-01 | 2008-02-21 | ケベンハウンス・ウニヴェルジテート | レプトスピラ属感染の治療による多発性硬化症の治療及び予防方法 |
| US8603978B2 (en) * | 2006-12-01 | 2013-12-10 | The United States of America, as represented by the Secretary, Department of Health and Humand Services | Use of muramyl dipeptide (MDP) for treating inflammation |
| JP2008251608A (ja) | 2007-03-29 | 2008-10-16 | Casio Comput Co Ltd | 半導体装置およびその製造方法 |
| WO2008150181A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treating anthrax exposure associated conditions |
| WO2008150182A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treatment of anthrax |
-
2009
- 2009-06-16 NZ NZ577731A patent/NZ577731A/en not_active IP Right Cessation
- 2009-12-16 US US12/639,733 patent/US8389479B2/en not_active Expired - Fee Related
- 2009-12-17 CA CA2688766A patent/CA2688766C/en not_active Expired - Fee Related
-
2010
- 2010-01-16 BR BRPI1009606A patent/BRPI1009606A2/pt not_active Application Discontinuation
- 2010-01-16 CN CN201080026791.5A patent/CN102458476B/zh not_active Expired - Fee Related
- 2010-06-16 SI SI201030779T patent/SI2442832T1/sl unknown
- 2010-06-16 PL PL10789788T patent/PL2442832T3/pl unknown
- 2010-06-16 WO PCT/NZ2010/000112 patent/WO2010147484A1/en not_active Ceased
- 2010-06-16 DK DK10789788.6T patent/DK2442832T3/da active
- 2010-06-16 HR HRP20141035AT patent/HRP20141035T1/hr unknown
- 2010-06-16 PT PT107897886T patent/PT2442832E/pt unknown
- 2010-06-16 IN IN167DEN2012 patent/IN2012DN00167A/en unknown
- 2010-06-16 EP EP10789788.6A patent/EP2442832B1/en active Active
- 2010-06-16 JP JP2012516022A patent/JP5646617B2/ja not_active Expired - Fee Related
- 2010-06-16 MX MX2011013661A patent/MX2011013661A/es active IP Right Grant
- 2010-06-16 AU AU2010260585A patent/AU2010260585B2/en not_active Ceased
- 2010-06-16 ES ES10789788.6T patent/ES2521565T3/es active Active
-
2011
- 2011-12-15 IL IL216993A patent/IL216993A/en not_active IP Right Cessation
-
2014
- 2014-11-03 CY CY20141100908T patent/CY1115714T1/el unknown
- 2014-11-04 SM SM201400165T patent/SMT201400165B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2442832A4 (en) | 2013-07-03 |
| IN2012DN00167A (https=) | 2015-04-17 |
| US20100317589A1 (en) | 2010-12-16 |
| HK1167101A1 (en) | 2013-02-01 |
| CY1115714T1 (el) | 2017-01-25 |
| CA2688766C (en) | 2015-06-30 |
| MX2011013661A (es) | 2012-05-22 |
| AU2010260585B2 (en) | 2013-02-21 |
| PT2442832E (pt) | 2014-11-11 |
| PL2442832T3 (pl) | 2015-01-30 |
| WO2010147484A8 (en) | 2012-07-19 |
| JP2012530132A (ja) | 2012-11-29 |
| AU2010260585A1 (en) | 2012-01-19 |
| SMT201400165B (it) | 2015-01-15 |
| CA2688766A1 (en) | 2010-12-16 |
| DK2442832T3 (da) | 2014-11-10 |
| ES2521565T3 (es) | 2014-11-12 |
| HRP20141035T1 (hr) | 2014-12-19 |
| EP2442832A1 (en) | 2012-04-25 |
| NZ577731A (en) | 2010-08-27 |
| EP2442832B1 (en) | 2014-08-06 |
| AU2010260585A8 (en) | 2012-06-14 |
| JP5646617B2 (ja) | 2014-12-24 |
| CN102458476B (zh) | 2014-08-20 |
| WO2010147484A1 (en) | 2010-12-23 |
| IL216993A (en) | 2016-03-31 |
| CN102458476A (zh) | 2012-05-16 |
| IL216993A0 (en) | 2012-02-29 |
| SI2442832T1 (sl) | 2014-12-31 |
| US8389479B2 (en) | 2013-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1009606A2 (pt) | método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição | |
| BRPI1014824A2 (pt) | composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo | |
| BRPI0911757A2 (pt) | composiÇÕes e mÉtodos para tratar distérbios digestivos. | |
| BRPI0911612A2 (pt) | composições e métodos para o tratamento da esclerose múltipla. | |
| BRPI0815283A2 (pt) | Equipamento para o tratamento da biomassa, método para o tratamento da biomassa, biomassa tratada e hidrolisado | |
| BRPI1008974A2 (pt) | composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3 | |
| BRPI0920326A2 (pt) | composição e método para tratamento da síndrome do olho ressecado | |
| BRPI0811589A2 (pt) | Composição farmacêutica e método para tratar câncer | |
| BRPI0810806A2 (pt) | Método para tratar uma lesão cutânea em um indivíduo | |
| BRPI0818732A2 (pt) | Composições de análogo de prostaglandina e métodos para tratar condições relacionadas epiteliais. | |
| BRPI1004899A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac | |
| BRPI0921317A2 (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero | |
| IL218257A (en) | A solid pharmaceutical preparation containing sglt-2 inhibitor and metformin and this drug for the treatment of metabolic disorders | |
| BRPI0922301A2 (pt) | combinações de inibidor de hsp90 | |
| BR112013026341A2 (pt) | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia | |
| BRPI0716210A2 (pt) | Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica | |
| HUE054298T2 (hu) | Készítmények és módszerek stroke kezelésére egy konkomittáns sztatin terápián tartott alanyban | |
| BRPI0809655A2 (pt) | Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit | |
| IL225597A0 (en) | Pharmaceutical preparation, methods of treatment and its uses | |
| PT2170055T (pt) | Composição para utilização no tratamento de lesão do tecido conjuntivo | |
| BRPI1011325A2 (pt) | composições e métodos para o tratamento de inflamação | |
| BRPI1000030A2 (pt) | métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição. | |
| BRPI0919759A2 (pt) | polipeptídeos para tratamento e prevenção de adesões | |
| BRPI0822349A2 (pt) | composições e métodos para tratar doenças lisossômicas | |
| ZA201008810B (en) | Pharmaceutical transdermal compositions and method for treating inflammation in cattle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |